Expression of functional Y1 receptors for neuropeptide Y in human Ewing's sarcoma cell lines

1992 ◽  
Vol 118 (7) ◽  
pp. 529-536 ◽  
Author(s):  
F. van Valen ◽  
W. Winkelmann ◽  
H. Jürgens
Keyword(s):  
Neuropeptide Y ◽  
Cell Lines ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Sarcoma Cell ◽  
Y1 Receptors

scholarly journals Inhibition of heat shock proteins (HSP) expression by quercetin and differential doxorubicin sensitization in neuroblastoma and Ewing’s sarcoma cell lines

2007 ◽  
Vol 103 (4) ◽  
pp. 1344-1354 ◽  
Author(s):  
Cristina Zanini ◽  
Giuliana Giribaldi ◽  
Giorgia Mandili ◽  
Franco Carta ◽  
Nicoletta Crescenzio ◽  
...  
Keyword(s):  
Heat Shock ◽  
Heat Shock Proteins ◽  
Cell Lines ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Sarcoma Cell ◽  
Shock Proteins

scholarly journals Discovery and Validation of a Compound to Target Ewing’s Sarcoma

Pharmaceutics ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 1553
Author(s):  
Ellie Esfandiari Nazzaro ◽  
Fahad Y. Sabei ◽  
Walter K. Vogel ◽  
Mohamad Nazari ◽  
Katelyn S. Nicholson ◽  
...  
Keyword(s):  
Cell Lines ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Apoptotic Cell ◽  
Intensive Therapy ◽  
Xenograft Model ◽  
Chemotherapeutic Agents ◽  
Cytotoxic Agents ◽  
Sarcoma Cell

Ewing’s sarcoma, characterized by pathognomonic t (11; 22) (q24; q12) and related chromosomal ETS family translocations, is a rare aggressive cancer of bone and soft tissue. Current protocols that include cytotoxic chemotherapeutic agents effectively treat localized disease; however, these aggressive therapies may result in treatment-related morbidities including second-site cancers in survivors. Moreover, the five-year survival rate in patients with relapsed, recurrent, or metastatic disease is less than 30%, despite intensive therapy with these cytotoxic agents. By using high-throughput phenotypic screening of small molecule libraries, we identified a previously uncharacterized compound (ML111) that inhibited in vitro proliferation of six established Ewing’s sarcoma cell lines with nanomolar potency. Proteomic studies show that ML111 treatment induced prometaphase arrest followed by rapid caspase-dependent apoptotic cell death in Ewing’s sarcoma cell lines. ML111, delivered via methoxypoly(ethylene glycol)-polycaprolactone copolymer nanoparticles, induced dose-dependent inhibition of Ewing’s sarcoma tumor growth in a murine xenograft model and invoked prometaphase arrest in vivo, consistent with in vitro data. These results suggest that ML111 represents a promising new drug lead for further preclinical studies and is a potential clinical development for the treatment of Ewing’s sarcoma.

Abstract A30: Integrative genomic analysis of two Ewing's sarcoma cell lines that show differential drug sensitivity

2014 ◽  
Author(s):  
TABREZ A. MOHAMMAD ◽  
Aparna Gorthi ◽  
Andrew Robles ◽  
Xavier Bernard ◽  
Tzu-hung Hsiao ◽  
...  
Keyword(s):  
Cell Lines ◽  
Drug Sensitivity ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Genomic Analysis ◽  
Sarcoma Cell

scholarly journals Fas-Mediated Apoptosis in Ewing's Sarcoma Cell Lines by Metalloproteinase Inhibitors

1999 ◽  
Vol 91 (19) ◽  
pp. 1678-1684 ◽  
Author(s):  
N. Mitsiades ◽  
V. Poulaki ◽  
A. Leone ◽  
M. Tsokos
Keyword(s):  
Cell Lines ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Sarcoma Cell ◽  
Metalloproteinase Inhibitors

scholarly journals Overexpression of miR-199b-5p inhibits Ewing's sarcoma cell lines by targeting CCNL1

2015 ◽  
Vol 12 (3) ◽  
pp. 3359-3364 ◽  
Author(s):  
WEIHUA LI ◽  
YUXIA LI ◽  
JIANKUO GUO ◽  
HUAGANG PAN ◽  
YONGLE ZHANG ◽  
...  
Keyword(s):  
Cell Lines ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Sarcoma Cell

scholarly journals Let-7a Functions as a Tumor Suppressor in Ewing's Sarcoma Cell Lines Partly by Targeting Cyclin-Dependent Kinase 6

2014 ◽  
Vol 33 (3) ◽  
pp. 136-147 ◽  
Author(s):  
Zhongzu Zhang ◽  
Lu Huang ◽  
Zhiming Yu ◽  
Xiang Chen ◽  
Dong Yang ◽  
...  
Keyword(s):  
Tumor Suppressor ◽  
Cell Lines ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Cyclin Dependent Kinase ◽  
Sarcoma Cell

scholarly journals Cytotoxicity of Tumor Necrosis Factor related apoptosis-inducing ligand towards Ewing's sarcoma cell lines

Oncogene ◽  
2001 ◽  
Vol 20 (8) ◽  
pp. 1010-1014 ◽  
Author(s):  
Arvind Kumar ◽  
Alan Jasmin ◽  
Michael T Eby ◽  
Preet M Chaudhary
Keyword(s):  
Tumor Necrosis Factor ◽  
Cell Lines ◽  
Tumor Necrosis ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Sarcoma Cell ◽  
Necrosis Factor

Neural and mesenchymal differentiations in Ewing's sarcoma cell lines. Morphological, immunophenotypic, molecular biological and cytogenetic evidence

1995 ◽  
Vol 63 (5) ◽  
pp. 738-743 ◽  
Author(s):  
A. Pagani ◽  
R. Fischer-Colbrie ◽  
U. Eder ◽  
A. Pellin ◽  
A. Llombart-Bosch ◽  
...  
Keyword(s):  
Cell Lines ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Sarcoma Cell ◽  
Cytogenetic Evidence

scholarly journals Analysis of the effects of mithramycin on Ewing’s sarcoma cell lines (802.3)

2014 ◽  
Vol 28 (S1) ◽  
Author(s):  
Mary Depner ◽  
Daniel Namazi ◽  
Anne Kruchten
Keyword(s):  
Cell Lines ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Sarcoma Cell

scholarly journals Replication Study: Systematic identification of genomic markers of drug sensitivity in cancer cells

eLife ◽  
2018 ◽  
Vol 7 ◽  
Author(s):  
John P Vanden Heuvel ◽  
Ewa Maddox ◽  
Samar W Maalouf ◽  
Elizabeth Iorns ◽  
Rachel Tsui ◽  
...  
Keyword(s):  
Cell Lines ◽  
Drug Sensitivity ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Mesenchymal Cells ◽  
Original Study ◽  
Sarcoma Cell ◽  
Sarcoma Cell Line ◽  
Genomic Markers ◽  
Systematic Identification

In 2016, as part of the Reproducibility Project: Cancer Biology, we published a Registered Report (Vanden Heuvel et al., 2016), that described how we intended to replicate selected experiments from the paper ‘Systematic identification of genomic markers of drug sensitivity in cancer cells’ (Garnett et al., 2012). Here we report the results. We found Ewing’s sarcoma cell lines, overall, were more sensitive to the PARP inhibitor olaparib than osteosarcoma cell lines; however, while the effect was in the same direction as the original study (Figure 4C; Garnett et al., 2012), it was not statistically significant. Further, mouse mesenchymal cells transformed with either the EWS-FLI1 or FUS-CHOP rearrangement displayed similar sensitivities to olaparib, whereas the Ewing’s sarcoma cell line SK-N-MC had increased olaparib sensitivity. In the original study, mouse mesenchymal cells transformed with the EWS-FLI1 rearrangement and SK-N-MC cells were found to have similar sensitivities to olaparib, whereas mesenchymal cells transformed with the FUS-CHOP rearrangement displayed a reduced sensitivity to olaparib (Figure 4E; Garnett et al., 2012). We also studied another Ewing’s sarcoma cell line, A673: A673 cells depleted of EWS-FLI1 or a negative control both displayed similar sensitivities to olaparib, whereas the original study reported a decreased sensitivity to olaparib when EWS-FLI1 was depleted (Figure 4F; Garnett et al., 2012). Differences between the original study and this replication attempt, such as the use of different sarcoma cell lines and level of knockdown efficiency, are factors that might have influenced the outcomes. Finally, where possible, we report meta-analyses for each result.

Sign in / Sign up

Export Citation Format

Share Document